Gene+Seq-200是吉因加推出的一款高效的基因测序仪,采用先进的生化和光学系统,产出高质量下机数据。结合吉因加针对肿瘤应用的十大优化,可对肿瘤样本进行准确、快速、安全的全方位分析。 核心特点 精益求精——采用DNBSEQ核心技术,有效避免PCR错误累积,在变异检出准确性方面具有显著优势。 通量更灵活——两种芯片FCL(500M)...
2019年9月20日,国内肿瘤精准医疗行业领先企业吉因加在厦门国际会议中心举办 “Gene+Seq-200/2000基因测序仪获NMPA证书上市发布会”。活动正值2019CSCO学术年会吉因加专题卫星会,整个会场气氛高涨,座无虚席。来自国内外的上千名专家、学者、...
近日,苏州工业园区科技领军企业吉因加研发的Gene+ Seq-200/2000基因测序仪获得国家药品监督管理局(NMPA)颁发的三类医疗器械注册证。Gene+ Seq-200/2000基因测序仪专注肿瘤领域,代表了测序仪技术应用(液体活检)的最高标准。此次获证,是公司贯彻国产NGS大平台战略和持续深耕肿瘤精准医疗领域的坚实步伐,也象征着我国自主品...
梁智勇教授为“Gene+Seq-200/2000基因测序仪获NMPA证书上市发布会”作开场致辞。他对吉因加两款国产基因测序仪的获证表示祝贺,并呼吁大家对国产品牌测序仪给予更多的支持,同时期待吉因加继续努力,真正把Gene+Seq-200/2000基因测序仪做成肿瘤基因检测的国之重器。 Gene+Seq-200/2000基因测序仪获NMPA证书上市发布仪式 工...
f, The left shows the scaled gene expression of positional marker genes in mouse (top) and human (bottom) scRNA-seq data. The right shows the same in organoid reconstruction based on mouse (top) or human (bottom) expression data. g, Correlation matrix for mouse (top) and human (bottom)...
Tag-seq has less sequence composition bias, leading to a better representation of AT-rich tag sequences, and allows accurate profiling of a subset of the transcriptome characterized by AT-rich genes expressed at levels below the threshold of detection of LongSAGE....
500 ng RNA per sample was used to create RNA-seq libraries through the Illumina TruSeq mRNA stranded protocol. Samples were sequenced on the NovoSeq S4 chip (WT vs KO Fig. 1c and neuron treatment Supplementary Fig. 1) or Illumina HiSeq 4000 platform (antibody treatment Fig. 1j). Cell...
Pooled libraries were sequenced using an Illumina NovaSeq S1 (PE 50), Novaseq S4 (200 cycle kit), NextSeq in high output mode (PE 75), NovaSeq S1 with 100 cycle kit (PE50). PRO-seq data analysis Preprocessing: Raw paired-end sequences in FASTQ format were trimmed using cutadapt (...
HiSeq 2500系统是一台强大而高效的超高通量测序系统,支持广泛的应用和研究规模。利用Illumina成熟的SBS原理,无以伦比的数据质量让HiSeq 2500成为全球大型基因组中心和领先机构的首选仪器。已经推出的v4试剂 将支持在更短时间内获得更多reads和更多数据。 HiSeq 2500性能参数 ...
近日,国家药品监督管理局(NMPA)官网公开信息显示,已批准吉因加自主品牌国产基因测序仪Gene+Seq-2000和Gene+Seq-200的适用范围变更申请。两款仪器分别于4月14日和4月27日通过审批,新增“对核糖核酸(RNA)进行测序”的适用范围。这标志着Gene+系列测序平台临床应用范围进一步拓展,将更好用于病原RNA检测,临床肿瘤、遗传病...